Stock Market Reviews

ENGN (enGene Holdings Inc.) News

Get the latest news, insights, and market updates on ENGN (enGene Holdings Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• enGene Named a BioSpace 2026 Best Places to Work Winner
  BOSTON & MONTREAL, November 04, 2025--enGene Holdings Inc. ("enGene" or the "Company") (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, today announced that BioSpace has named the company to its 2026 Best Places to Work. enGene is among 50 U.S. operating employers recognized as one of the most desirable workplaces in the life sciences industry.
  Nov 4, 2025 - $ENGN
• enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  BOSTON & MONTREAL, October 01, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Hussein Sweiti, M.D., MSc, Chief Medical Officer, with a grant date of September 30, 2025. The inducement award for Dr. Sweiti consists of a non-qualified stock option to purchase an aggregate 600,000 of the Company's common shares. The inducement aw
  Oct 1, 2025 - $ENGN
• enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
  BOSTON & MONTREAL, September 30, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025.
  Sep 30, 2025 - $ENGN
• enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
  BOSTON & MONTREAL, September 11, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update.
  Sep 11, 2025 - $ENGN
• enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
  BOSTON & MONTREAL, September 03, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral gene therapy company, today announced it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid ("detalimogene" and previously EG-70) in patients with high-risk, non-muscle invasive bladder cancer (NMIBC). LEGEND’s pivotal Cohort 1 is studying detali
  Sep 3, 2025 - $ENGN
• This enGene Holdings Insider Increased Their Holding In The Last Year
  NasdaqCM:ENGN 1 Year Share Price vs Fair Value Explore enGene Holdings's Fair Values from the Community and select...
  Aug 19, 2025 - $ENGN
• enGene Announces Board and Leadership Appointments to Support Commercial Readiness
  BOSTON & MONTREAL, July 08, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene’s strategic transition toward planned commerciali
  Jul 8, 2025 - $ENGN
• FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
  BOSTON & MONTREAL, June 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the Company’s lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, no
  Jun 25, 2025 - $ENGN
• enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
  BOSTON & MONTREAL, June 12, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update.
  Jun 12, 2025 - $ENGN
• enGene Announces the Resignation of its Chief Medical Officer
  BOSTON & MONTREAL, June 04, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his role as Chief Medical Officer on June 3, 2025. Dr. Pruthi’s resignation as Chief Medical Officer will take effect on June 16, 2025. He will be supporting the organization to ensure an orderly transition of his responsibilities before he departs. The Company intends to reallocate Dr. Pruthi’
  Jun 4, 2025 - $ENGN